Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Zhi Byed 11

PreclinicalSmall molecule

NNICHD Global Network for Women's and Children's Health

Zhi Byed 11 is one of 2 small molecule programs targeting Misoprostol. It is currently in Preclinical.

1

Indications

1

Total Trials

0

Active Trials

1

Competitors

Pipeline

Status by Indication[3][1]

Indication

MisoprostolCompleted

MisoprostolPreclinical

Completed

Competition

Competitive Landscape

2 competitors in Misoprostol

#DrugCompanyPhaseTrials

I.V Oxytocin Administration

BBezmialem Vakif University

Zhi Byed 11

NNICHD Global Network for Women's and Children's Health

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Misoprostol1 trial

RCT of Zhi Byed 11 (ZB11) Versus Misoprostol in Tibet

Completed·NNICHD Global Network for Women's and Children's Health·N/A·NCT00147420·848 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Zhi Byed 11. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Zhi Byed 11 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Zhi Byed 11. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — NICHD Global Network for Women's and Children's Health company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: NNICHD Global Network for Women's and Children's Health

Related News